Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%76 EV-to-OCF is 8.14 as of Aug. 09, 2026, which is 23% below its 10-year median of 10.57. GuruFocus rates SHTDF with a GF Score™ of 76/100 and a GF Value™ of $2.83 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Sinopharm Group Co ranks worse than 52.54% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sinopharm Group Co's Enterprise Value is $17,101 Mil.
Sinopharm Group Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $2,100 Mil. Therefore, Sinopharm Group Co's EV-to-OCF for today is 8.14.
The historical rank and industry rank for Sinopharm Group Co's EV-to-OCF or its related term are showing as below:
SHTDF'
s EV-to-OCF Range Over the Past 10 Years
Min: 4.69 Med: 10.57 Max: 41.59
Current: 8.38
During the past 13 years, the highest EV-to-OCF of Sinopharm Group Co was 41.59. The lowest was 4.69. And the median was 10.57.
SHTDF's EV-to-OCF is ranked worse than 52.54% of 118
companies
in the Medical Distribution industry
Industry Median: 7.475
vs SHTDF: 8.38
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinopharm Group Co (OTCPK:SHTDF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinopharm Group Co's PE Ratio (TTM) for today is calculated as:
Sinopharm Group Co's share price for today is $2.133.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.323.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sinopharm Group Co EV-to-OCF Related Terms
Sinopharm Group Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co EV-to-OCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's EV-to-OCF falls into.
Sinopharm Group Co's current Enterprise Value is $17,101 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Group Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $2,100 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a EV-to-OCF of 8.14 as of Aug. 09, 2026. This is 23% below median its historical median of 10.57. Over the past decade, Sinopharm Group Co's EV-to-OCF has ranged from 4.69 to 41.59. According to the industry distribution chart, Sinopharm Group Co ranks #62 out of 118 companies in the Medical Distribution industry, placing it in the top 52.5%.
Is Sinopharm Group Co's EV-to-OCF too high?
Sinopharm Group Co's current EV-to-OCF of 8.14 is 23% below median its 10-year median of 10.57. Over the past 10 years, this metric has ranged from a low of 4.69 to a high of 41.59. The Medical Distribution industry median EV-to-OCF is 7.48. Sinopharm Group Co's value of 8.14 is 8.9% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #62 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's EV-to-OCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #62 out of 118 companies for EV-to-OCF. This places Sinopharm Group Co in the lower half of its industry. The industry median EV-to-OCF is 7.48. Sinopharm Group Co's value of 8.14 is 8.9% above this benchmark. Historically, Sinopharm Group Co's own EV-to-OCF has ranged from 4.69 to 41.59 over the past decade. While the company's 10-year median is 10.57 vs. the industry median of 7.48, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Distribution company?
The median EV-to-OCF among Medical Distribution companies is 7.48, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current EV-to-OCF of 8.14 is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median EV-to-OCF is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current EV-to-OCF is 8.14, which is 23% below median its own 10-year median of 10.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.83, compared to a current price of $2.13 — trading 24.6% below its estimated fair value. The current EV-to-OCF is 8.14, which is 23% below median its 10-year median of 10.57 and 8.9% above the Medical Distribution industry median of 7.48. Sinopharm Group Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current EV-to-OCF is 8.14 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 24.6% below its estimated GF Value™ of $2.83.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
EV-to-OCF: 8.14 (23% below median its 10-year median of 10.57)
GF Value™: $2.83 vs. price of $2.13 (24.6% below fair value)
Industry Position: 8.9% above the Medical Distribution median (#62 of 118)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
76GF Score
Get the complete analysis for SHTDF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
